Primary Biliary Cholangitis Therapeutics
1. Iqirvo patent expiration
Treatment: Treatment of primary biliary cholangitis (pbc) in combination with ursodeoxycholic acid (udca) in adults who have had an inadequate response...
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US7943661 | IPSEN | Substituted 1,3-diphenylprop-2-en-1-one derivatives and preparation and uses thereof |
Sep, 2024
(1 year, 4 months ago) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US11857523 | IPSEN | Methods of treatment of cholestatic diseases |
Mar, 2037
(11 years from now) | |
| US11331292 | IPSEN | Methods of treatment of cholestatic diseases |
Mar, 2037
(11 years from now) | |
| US11185519 | IPSEN | Methods of treatment of cholestatic diseases |
Mar, 2037
(11 years from now) | |
| US12310935 | IPSEN | Methods of treatment of cholestatic diseases |
Mar, 2037
(11 years from now) | |
| US12295928 | IPSEN | Methods of treatment of cholestatic diseases |
Mar, 2037
(11 years from now) | |
| US12295927 | IPSEN | Methods of treatment of cholestatic diseases |
Mar, 2037
(11 years from now) | |
| US7632870 | IPSEN | Composition based on substituted 1,3-diphenylprop-2-en-1-one derivatives, preparation and uses thereof |
Sep, 2024
(1 year, 4 months ago) | |
| US11850223 | IPSEN | Methods of treatment of cholestatic diseases |
Mar, 2037
(11 years from now) | |
| US12233038 | IPSEN | Methods of treatment of cholestatic diseases |
Mar, 2037
(11 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Jun 10, 2029 |
| Orphan Drug Exclusivity(ODE-486) | Jun 10, 2031 |
Drugs and Companies using ELAFIBRANOR ingredient
NCE-1 date: 10 June, 2028
Market Authorisation Date: 10 June, 2024
Dosage: TABLET
More Information on Dosage
IQIRVO family patents
2. Livdelzi patent expiration
Treatment: Treatment of primary biliary cholangitis (pbc)
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US7709682 | GILEAD SCIENCES INC | Lysine salts of 4-((phenoxyalkyl)thio)-phenoxyacetic acid derivatives |
Sep, 2026
(8 months from now) | |
| US7301050 | GILEAD SCIENCES INC | 4-((phenoxyalkyl)thio)-phenoxyacetic acids and analogs |
Aug, 2026
(6 months from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US11596614 | GILEAD SCIENCES INC | Treatment of intrahepatic cholestatic diseases |
Mar, 2035
(9 years from now) | |
| US11406611 | GILEAD SCIENCES INC | Treatment of intrahepatic cholestatic diseases |
Mar, 2035
(9 years from now) | |
| US10272058 | GILEAD SCIENCES INC | Treatment of intrahepatic cholestatic diseases |
Mar, 2035
(9 years from now) | |
| US9486428 | GILEAD SCIENCES INC | Treatment of intrahepatic cholestatic diseases |
Mar, 2035
(9 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Aug 14, 2029 |
| Orphan Drug Exclusivity(ODE-486) | Aug 14, 2031 |
Drugs and Companies using SELADELPAR LYSINE ingredient
NCE-1 date: 14 August, 2028
Market Authorisation Date: 14 August, 2024
Dosage: CAPSULE
More Information on Dosage
LIVDELZI family patents
3. Ocaliva patent
expiration
Treatment: Treatment of primary biliary cholangitis (pbc); Treatment of primary biliary cholangiti...
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US7138390 | INTERCEPT PHARMS INC | Steroids as agonists for FXR |
Nov, 2022
(3 years ago) | |
| US10174073 | INTERCEPT PHARMS INC | Preparation and uses of obeticholic acid |
Jun, 2033
(7 years from now) | |
| USRE48286 | INTERCEPT PHARMS INC | Steroids as agonists for FXR |
Feb, 2027
(1 year, 1 month from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8058267 | INTERCEPT PHARMS INC | Steroids as agonists for FXR |
Feb, 2022
(3 years ago) | |
| US8377916 | INTERCEPT PHARMS INC | Steroids as agonists for FXR |
Feb, 2022
(3 years ago) | |
| US10047117 | INTERCEPT PHARMS INC | Preparation and uses of obeticholic acid |
Sep, 2033
(7 years from now) | |
| US10758549 | INTERCEPT PHARMS INC | Compositions of obeticholic acid and methods of use |
Apr, 2036
(10 years from now) | |
| US10751349 | INTERCEPT PHARMS INC | Compositions of obeticholic acid and methods of use |
Apr, 2036
(10 years from now) | |
| US10052337 | INTERCEPT PHARMS INC | Compositions of obeticholic acid and methods of use |
Apr, 2036
(10 years from now) | |
| US9238673 | INTERCEPT PHARMS INC | Preparation and uses of obeticholic acid |
Jun, 2033
(7 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | May 27, 2021 |
| Orphan Drug Exclusivity(ODE) | May 27, 2023 |
| Orphan Drug Exclusivity(ODE-119) | May 27, 2023 |
Drugs and Companies using OBETICHOLIC ACID ingredient
NCE-1 date: 27 May, 2020
Market Authorisation Date: 27 May, 2016
Dosage: TABLET
How can I launch a generic of OCALIVA before it's drug patent expiration?
More Information on Dosage
OCALIVA family patents